Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World June 17, 2015 James Urquhart	Promising compound offers single dose knock-out for malaria Ian Gilbert and colleagues, working with the Medicines for Malaria Venture, have found a compound dubbed DDD107498 which kills Plasmodium falciparum -- the species responsible for most dangerous form of malaria.
Chemistry World April 25, 2007 Richard Van Noorden	Malaria Drug Cures Mice with Single Dose U.S. chemists have adapted a Chinese herbal medicine to create a new generation of antimalarial drugs which could solve some of the current crop's failings.
BusinessWeek January 17, 2005 Einhorn & Kripalani	Wanted: New Weapons Against An Old Killer Many of the new malaria medicines are in early stages of development. But with tsunami-hit countries receiving billions in aid there may finally be both the will and the means to tackle one of the world's most dangerous diseases.
Chemistry World June 13, 2008 Sarah Houlton	Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses.
Chemistry World September 3, 2014 Rajesh Parishwad	Piramal exits drug discovery in India India's Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services.
Chemistry World April 22, 2015 Phillip Broadwith	Daiichi Sankyo steps out after Sun-Ranbaxy merger Japanese firm Daiichi Sankyo has sold off its entire stake in India's Sun Pharmaceuticals, following Sun's takeover of Indian rival Ranbaxy, in which Daiichi was the controlling shareholder.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
Chemistry World April 9, 2014 Andy Extance	Sun set on Ranbaxy rescue India's Sun Pharma will acquire its compatriot Ranbaxy in a $3.2 billion all-share deal that will create the world's fourth largest generic drugs producer.
Chemistry World April 1, 2015 Sanjay Kumar	Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world.
BusinessWeek July 14, 2003 Einhorn & Kripalani	In India a Little Lab Work and Lots of Lawyers Ranbaxy, a maker of generic drugs, must win lawsuits to grow
Chemistry World January 27, 2014 Phillip Broadwith	US blocks imports from fourth Ranbaxy plant The US Food and Drug Administration has banned Indian drugmaker Ranbaxy from importing active pharmaceutical ingredients produced at its plant at Toansa, India, into the US.
Chemistry World April 25, 2008 James Mitchell Crow	Drug Costs Cut on World Malaria Day Swiss pharmaceuticals firm Novartis has announced it will reduce by one fifth the price it charges governments and NGOs for artemisinin-based antimalarial Coartem.
Chemistry World December 15, 2011	Eastern promise Yongyuth Yuthavong discusses the challenges that face scientists in Thailand with Kathleen Too.
Chemistry World November 1, 2011 Sarah Houlton	A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases.
Chemistry World April 2008 Victoria Gill	Malaria no More? A fresh round of research funding could put an end to the killer disease.
The Motley Fool September 18, 2008 Brian Orelli	Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved.
Pharmaceutical Executive October 1, 2011 Amrita Ghaswalla	Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied.
Chemistry World August 18, 2006 Bea Perks	Resistance is Futile Resistance to malaria drugs poses a serious problem in countries where the disease is endemic. But researchers have now reported the synthesis of a hybrid molecule that combines chloroquine with a molecule that reverses resistance.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
Pharmaceutical Executive September 1, 2006 Jill Wechsler	Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world.
Chemistry World July 28, 2008 Rebecca Trager	Ranbaxy troubles place FDA under fire Indian drug firm Ranbaxy is facing scrutiny by American federal agencies and lawmakers over allegations that the company falsified scientific evidence to gain US approval for its products.
Chemistry World May 31, 2013 Phillip Broadwith	Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases.
Chemistry World December 19, 2007 Hepeng Jia	Boom and Bust for Antimalarial Industry At first there was a global shortage, but now a surplus of artemisinin threatens to put some drug manufacturers out of business.
Scientific American October 2007 Jeffrey D. Sachs	Ending Malaria Deaths in Africa One of the world s worst killers can be stopped soon if we make the investment.
BusinessWeek January 12, 2004 Manjeet Kripalani	India: Big Pharma's New Promised Land? Drugmakers are heeding the siren call of its well-trained, cheap chemists.
Chemistry World April 9, 2009 Phillip Broadwith	Dual-action malaria drug reverses resistance US chemists have designed a new class of antimalarial drug that can reverse the malaria parasite's resistance to existing drugs.
Pharmaceutical Executive September 1, 2008 Sarah Houlton	Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units.
Chemistry World August 21, 2015 Sa njay Kumar	Indian pharma under increased regulatory scrutiny A Europe-wide ban on hundreds of generic pharmaceutical formulations tested by Indian contract research firm GVK Biosciences comes into force today.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
Scientific American September 2007 Jeffrey D. Sachs	Ending Malaria Deaths in Africa One of the world's worst killers can be stopped soon if we make the investment.
Chemistry World July 3, 2006 Mark Peplow	Drug Screen Reveals Antimalarial Agent A widely-available antihistamine called astemizole could help in the battle against malaria, according to a survey of more than 2,600 drugs in a pharmaceutical library.
Fast Company September 2006 Tonya Garcia	Miracle Microbes In the labs of Amyris Biotechnologies, molecular manipulation may yield cheap and effective malaria drugs.
Chemistry World May 7, 2014 Phillip Broadwith	Insider trading allegations stall Sun -- Ranbaxy deal The merger deal that would create India's largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement.
Chemistry World November 21, 2014 Rebecca Trager	Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs
Wired March 2006 Jennifer Kahn	A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials.
The Motley Fool February 26, 2009 Brian Orelli	Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association.
Chemistry World May 23, 2013 Phillip Broadwith	$500m fine over generics fraud for Ranbaxy A long-running investigation by the US Department of Justice and Food and Drug Administration has ended with a $500 million fine for generic drugmaker Ranbaxy.
Chemistry World May 2007 Lisa Melton	Chinese Medicine in Western Packaging The past decade has seen a global awakening to the truly curative powers of many ancient medicines, from black bear bile to the Asian plant Epimedium.
Chemistry World April 10, 2013 Hayley Birch	Yeast to make malaria drug on demand A natural biochemical pathway that produces the antimalarial drug artemisinin in the sweet wormwood plant has been fully reconstructed in yeast.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
HHMI Bulletin Aug 2010 Robert Koenig	Collaborating Across an Ocean to Stop Malaria Two scholars, one from Mali and one from the United States team up to produce a vaccine for malaria.
Pharmaceutical Executive February 1, 2007 Joanna Breitstein	Net Effect Ripley Ballou may finally win approval for a vaccine he started testing as an army physician more than 25 years ago - an advance that could mark the beginning of a whole new phase in the battle against one of the world's great killers: malaria.
Chemistry World August 7, 2009 Lewis Brindley	Malaria disaster risk Two studies could spell disaster for malaria management, with the first evidence of a malarial strain resistant to a first-line drug, and signs that a widely used insect repellent could be neurotoxic.
Chemistry World September 18, 2008 James Mitchell Crow	Ranbaxy hit by US drug ban The US Food and Drug Administration (FDA) has banned the import of more than 30 drugs made by Ranbaxy, India's largest drugmaker.
Salon.com December 15, 2000 Arthur Allen	Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research...
The Motley Fool April 6, 2010 Brian Orelli	Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
Chemistry World July 2010	Supporting science The Wellcome Trust is one of the largest science funding bodies in the world. Sir Mark Walport, the trust's director, tells Phillip Broadwith how it spends its money
Bio-IT World Dec 2005/Jan 2006 Salvatore Salamone	Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises.
The Motley Fool January 21, 2010 Brian Orelli	The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments.
Chemistry World October 9, 2013 Phillip Broadwith	GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months.